|
Obesity
|
|
0.060 |
GeneticVariation
|
BEFREE |
Accumulated evidence suggests that the polymorphism rs2016520 in PPARD is associated with lipid metabolism, obesity, metabolic syndrome, and type 2 diabetes mellitus.
|
28128413 |
2017 |
|
Obesity
|
|
0.060 |
GeneticVariation
|
BEFREE |
C-C haplotype, constructed from rs2016520 and rs9794 alleles, showed a significant protective effect for both abnormal weight and abdominal obesity.
|
26073637 |
2016 |
|
Obesity
|
|
0.060 |
GeneticVariation
|
BEFREE |
Polymorphism of rs2016520 in gene PPARD has been associated with lipid metabolism, obesity, metabolic syndrome and type 2 diabetes mellitus (T2DM).
|
26915488 |
2016 |
|
Obesity
|
|
0.060 |
GeneticVariation
|
BEFREE |
rs2016520 and rs10865170 were associated with lower obesity risk.
|
23545576 |
2013 |
|
Obesity
|
|
0.060 |
GeneticVariation
|
BEFREE |
After adjustment for gender, age, and smoking status, it was found that the carriers of the C allele (TC + CC) of rs2016520 were associated with a decreased risk of abdominal obesity compared to the carriers of the TT genotype (mean difference = -2.63, 95% CI = -3.61--1.64, P < 0.0001).
|
23273766 |
2012 |
|
Obesity
|
|
0.060 |
GeneticVariation
|
BEFREE |
Previous studies have identified a single-nucleotide polymorphism in the gene encoding peroxisome proliferator-activated receptor-delta (PPARD), rs2016520, that is associated with changes in metabolic disease in some but not all studies, which suggests that PPARD agonists may have therapeutic benefits for the treatment of metabolic disorders, including dyslipidemia, type 2 diabetes, and obesity.
|
20200337 |
2010 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
|
0.040 |
GeneticVariation
|
BEFREE |
Accumulated evidence suggests that the polymorphism rs2016520 in PPARD is associated with lipid metabolism, obesity, metabolic syndrome, and type 2 diabetes mellitus.
|
28128413 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
|
0.040 |
GeneticVariation
|
BEFREE |
Polymorphism of rs2016520 in gene PPARD has been associated with lipid metabolism, obesity, metabolic syndrome and type 2 diabetes mellitus (T2DM).
|
26915488 |
2016 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
|
0.040 |
GeneticVariation
|
BEFREE |
Previous studies have identified a single-nucleotide polymorphism in the gene encoding peroxisome proliferator-activated receptor-delta (PPARD), rs2016520, that is associated with changes in metabolic disease in some but not all studies, which suggests that PPARD agonists may have therapeutic benefits for the treatment of metabolic disorders, including dyslipidemia, type 2 diabetes, and obesity.
|
20200337 |
2010 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
|
0.040 |
GeneticVariation
|
BEFREE |
There was an association between rs2016520 and height in both patients with type 2 diabetes and controls without diabetes (combined P = 5 x 10(-5)).
|
19383774 |
2009 |
|
Colorectal Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
In this study, whether the intratumoral heterogeneity of polymorphism of PPARD-87 T>C (rs2016520) existed and its influence in CRC were investigated.
|
30868900 |
2019 |
|
Colorectal Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
In conclusion, for the first time, the association between the +294T/C (rs2016520) polymorphism and colorectal cancer has been studied in Mexican patients.
|
28128413 |
2017 |
|
Diabetes Mellitus
|
|
0.020 |
GeneticVariation
|
BEFREE |
No significant difference was found in either allelic frequency (P = 0.298) or genotype distribution (P = 0.151) of PPARD rs2016520 between T2DM patients and healthy subjects.
|
25311380 |
2015 |
|
Diabetes Mellitus
|
|
0.020 |
GeneticVariation
|
BEFREE |
There was an association between rs2016520 and height in both patients with type 2 diabetes and controls without diabetes (combined P = 5 x 10(-5)).
|
19383774 |
2009 |
|
Cardiovascular Diseases
|
|
0.010 |
GeneticVariation
|
BEFREE |
The minor allele of rs2016520 and rs9794 in PPAR-δ and interaction between rs2016520 and non-smoking were associated with decreased risk of CVD.
|
28287878 |
2017 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.010 |
GeneticVariation
|
BEFREE |
In conclusion, for the first time, the association between the +294T/C (rs2016520) polymorphism and colorectal cancer has been studied in Mexican patients.
|
28128413 |
2017 |
|
Essential Hypertension
|
|
0.010 |
GeneticVariation
|
BEFREE |
We also found a potential SNP-SNP interaction between rs2016520 and rs9794; subjects with TC or CC of rs2016520 and CG or GG of rs9794 genotype have the lowest EH ris</span>k, compared to subjects with TT of rs2016520 and CC of rs9794 genotype; OR (95%CI) was 0.32 (0.23-0.62) after covariate adjustment.
|
26613934 |
2016 |
|
Coronary heart disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
We found that the PPARD rs2016520-GG genotype decreased CHD risk in a Han Chinese population.
|
26125839 |
2015 |
|
Coronary Artery Disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
Positive association between PPARD rs2016520 polymorphism and coronary heart disease in a Han Chinese population.
|
26125839 |
2015 |
|
Brain Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
We aimed to check the contribution of PPARD rs2016520 and lipid concentration to the risk of intracerebral hemorrhages (ICH) and brain tumors (BT) in Han Chinese.
|
25776471 |
2015 |
|
Coronary Arteriosclerosis
|
|
0.010 |
GeneticVariation
|
BEFREE |
Positive association between PPARD rs2016520 polymorphism and coronary heart disease in a Han Chinese population.
|
26125839 |
2015 |
|
Brain Diseases
|
|
0.010 |
GeneticVariation
|
BEFREE |
PPARD rs2016520 polymorphism and circulating lipid levels connect with brain diseases in Han Chinese and suggest sex-dependent effects.
|
25776471 |
2015 |
|
Dyslipidemias
|
|
0.010 |
GeneticVariation
|
BEFREE |
Previous studies have identified a single-nucleotide polymorphism in the gene encoding peroxisome proliferator-activated receptor-delta (PPARD), rs2016520, that is associated with changes in metabolic disease in some but not all studies, which suggests that PPARD agonists may have therapeutic benefits for the treatment of metabolic disorders, including dyslipidemia, type 2 diabetes, and obesity.
|
20200337 |
2010 |
|
Metabolic Diseases
|
|
0.010 |
GeneticVariation
|
BEFREE |
The objective of the study was to determine whether rs2016520 or other single-nucleotide polymorphism in the PPARD locus influenced the risk of developing various characteristics of metabolic disease.
|
20200337 |
2010 |
|
Diabetes
|
|
0.010 |
GeneticVariation
|
BEFREE |
There was an association between rs2016520 and height in both patients with type 2 diabetes and controls without diabetes (combined P = 5 x 10(-5)).
|
19383774 |
2009 |